Contents
On the medicine shelf, a GI cancer question rarely asks you to stage a tumor. It describes a patient somewhere on a known path to cancer (a polyp, a segment of Barrett esophagus, an H. pylori infection, cirrhosis) and asks what happens next: the surveillance interval, the test that catches progression, or the treatment that interrupts it. Know where the patient sits on the pathway and the answer follows.
The adenoma-carcinoma sequence
Most colorectal cancers follow this chromosomal instability pathway, usually over about 10 years. That decade is the reason screening works.
- Normal mucosaAPC loss starts the process
- Early adenomaAPC lost; crypts proliferate
- Larger adenomaKRAS mutation drives growth
- Advanced adenoma18q loss (DCC, SMAD4)
- CarcinomaTP53 loss allows invasion
A second route, the microsatellite instability pathway, runs through defective mismatch repair. About 15% of colorectal cancers are MSI-high, but most of those are sporadic (MLH1 promoter hypermethylation, often through sessile serrated lesions with BRAF mutations). Lynch syndrome, the germline form, causes about 3%.
| Pathway | Key genes | Clinical picture | What the exam wants |
|---|---|---|---|
| Sporadic adenoma-carcinoma | APC, KRAS, TP53 | Older adult, often left-sided | Average-risk screening from age 45 |
| Familial adenomatous polyposis | Germline APC | Hundreds to thousands of polyps in adolescence | Yearly endoscopy from about age 10 to 12; colectomy |
| Lynch syndrome | MLH1, MSH2, MSH6, PMS2, EPCAM | Young patient, right-sided tumor, endometrial cancer in the family | Colonoscopy every 1 to 2 years from age 20 to 25 |
| Serrated pathway | BRAF, CpG island methylation | Flat right-sided sessile serrated lesions | Complete removal; these are the lesions colonoscopy misses |
For average-risk adults, the USPSTF recommends screening from 45 to 75 years, with selective screening from 76 to 85. Options include colonoscopy every 10 years, FIT every year, stool DNA-FIT every 1 to 3 years, and CT colonography or flexible sigmoidoscopy every 5 years. Any positive noninvasive test is followed by colonoscopy.
The Barrett progression
Chronic reflux replaces the squamous lining of the distal esophagus with intestinal-type columnar epithelium. Adenocarcinoma of the distal third is the end point.
- Chronic GERDAcid and bile injure squamous mucosa
- Barrett, no dysplasiaIntestinal metaplasia; PPI and surveillance
- Low-grade dysplasiaConfirm with an expert GI pathologist
- High-grade dysplasiaEndoscopic eradication therapy
- Esophageal cancerDistal third, glandular
The ACG suggests a single screening endoscopy for patients with chronic GERD plus three or more risk factors: male sex, age over 50, White race, smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. Surveillance for nondysplastic Barrett: every 5 years if the segment is under 3 cm, every 3 years if it is 3 cm or longer. Confirmed low-grade dysplasia: endoscopic eradication therapy is suggested, with yearly surveillance as an alternative. High-grade dysplasia: endoscopic resection of any visible lesion, then ablation. Esophagectomy is no longer the default answer for dysplasia.
Squamous cell carcinoma follows a different road: smoking, heavy alcohol use, achalasia and caustic injury, with tumors in the upper and middle esophagus.
The Correa cascade: H. pylori to gastric cancer
- H. pylori infectionChronic active gastritis
- Atrophic gastritisLoss of glands and acid
- Intestinal metaplasiaGoblet cells in the stomach
- DysplasiaPrecursor lesion
- Gastric cancerIntestinal type
H. pylori is also the cause of most gastric MALT lymphomas, and low-grade gastric MALT lymphoma often regresses with eradication alone. When susceptibility is unknown, the 2024 ACG guideline recommends 14 days of optimized bismuth quadruple therapy (PPI, bismuth, tetracycline, metronidazole) for treatment-naive patients. Clarithromycin triple therapy is used only when the strain is known to be clarithromycin-susceptible. Confirm eradication at least 4 weeks after treatment with a urea breath test, stool antigen or biopsy, after holding the PPI for 2 weeks.
The cirrhosis-to-HCC pathway
- Chronic liver injuryHBV, HCV, alcohol, MASLD
- CirrhosisRegenerative nodules and fibrosis
- Dysplastic nodulePremalignant
- Hepatocellular carcinomaArterial enhancement, washout
Hepatitis B can cause HCC without cirrhosis, so selected noncirrhotic HBV carriers are screened too. AASLD recommends surveillance with ultrasound, with or without AFP, every 6 months in cirrhosis. A new nodule of 1 cm or more goes to multiphase CT or MRI; arterial-phase hyperenhancement with washout in a cirrhotic liver is diagnostic, so a biopsy is not needed.
Primary sclerosing cholangitis is the biliary version of this story. It carries risk of cholangiocarcinoma, gallbladder cancer and, with coexisting inflammatory bowel disease, colorectal cancer. AASLD guidance: MRI with MRCP, with or without CA 19-9, every year, and colonoscopy every year in patients who also have IBD.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| Positive FIT in a 52-year-old | Possible advanced adenoma or cancer | Colonoscopy |
| Colon cancer at 38, mother with endometrial cancer at 45 | Lynch syndrome | Tumor MMR or MSI testing, genetic counseling, colonoscopy every 1 to 2 years for relatives at risk |
| Teenager with hundreds of colonic polyps | Familial adenomatous polyposis | Genetic testing; plan prophylactic colectomy |
| 4 cm Barrett segment, no dysplasia | Long-segment nondysplastic Barrett | PPI and surveillance endoscopy in 3 years |
| Barrett with high-grade dysplasia | One step from cancer | Endoscopic resection and ablation |
| Dyspepsia, positive stool antigen, no prior treatment | H. pylori | 14 days of bismuth quadruple therapy, then confirm eradication |
| Low-grade gastric MALT lymphoma, H. pylori positive | Antigen-driven lymphoma | Eradicate H. pylori |
| Cirrhosis, new 2 cm nodule with arterial enhancement and washout | Hepatocellular carcinoma | Diagnosis made on imaging; stage and treat, no biopsy needed |
| Ulcerative colitis, rising alkaline phosphatase, beaded ducts on MRCP | Primary sclerosing cholangitis | Yearly MRCP and yearly colonoscopy |
Where students lose points
- Calling every MSI-high tumor Lynch syndrome. Most are sporadic; Lynch syndrome accounts for about 3% of colorectal cancers.
- Sending Barrett with dysplasia to esophagectomy. Endoscopic eradication therapy is first-line for dysplasia and many early cancers.
- Repeating endoscopy for nondysplastic Barrett every year. The interval is 3 or 5 years, set by segment length.
- Choosing clarithromycin triple therapy without knowing susceptibility. Bismuth quadruple therapy is the default first-line regimen.
- Skipping the eradication test after H. pylori treatment, or testing while the patient is still on a PPI.
- Biopsying a classic HCC on multiphase imaging. In cirrhosis, the imaging pattern is enough.
- Forgetting the colon in PSC. With coexisting IBD, colorectal cancer surveillance is yearly.
Practice question
A 58-year-old man comes to the office to discuss the results of an upper endoscopy. He has had heartburn several times a week for 15 years and takes omeprazole daily. He smokes 1 pack of cigarettes daily and has a BMI of 33 kg/m². Endoscopy showed salmon-colored mucosa extending 4 cm above the gastroesophageal junction, with no nodules or ulceration. Biopsies show intestinal metaplasia with goblet cells and no dysplasia.
In addition to continuing the proton pump inhibitor, which of the following is the most appropriate management?
- Repeat endoscopy in 6 months
- Repeat endoscopy in 3 years
- Repeat endoscopy in 5 years
- Radiofrequency ablation
- Esophagectomy
Show the answer
Answer: B. He has nondysplastic Barrett esophagus with a segment of 3 cm or longer. The ACG recommends surveillance endoscopy every 3 years for this group, along with long-term acid suppression.
Why the others are wrong. A: a short interval is used to recheck indefinite or newly found dysplasia, not nondysplastic Barrett. C: 5 years is the interval for segments shorter than 3 cm. D: ablation is for confirmed dysplasia, not nondysplastic Barrett. E: esophagectomy is reserved for cancers that cannot be managed endoscopically.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
1Adenoma-carcinoma sequence
APC, then KRAS, then 18q (DCC, SMAD4), then TP53.Did you get it?2Average-risk colorectal screening
Ages 45 to 75; colonoscopy every 10 years or FIT yearly.Did you get it?3Lynch surveillance
Colonoscopy every 1 to 2 years from age 20 to 25.Did you get it?4Nondysplastic Barrett
Every 5 years if under 3 cm, every 3 years if 3 cm or longer.Did you get it?5H. pylori first-line
Bismuth quadruple therapy for 14 days, then confirm eradication.Did you get it?6HCC surveillance in cirrhosis
Ultrasound with or without AFP every 6 months.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review GI cancers by organ, or see MedRise for students.
Sources
- Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990 (PubMed 2188735)
- US Preventive Services Task Force. Colorectal cancer: screening. Final recommendation statement, 2021
- Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 (PubMed 25645574)
- Shaheen NJ, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol, 2022 (PubMed 35354777)
- Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)
- Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)
- Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023 (PubMed 36083140)
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



